StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Intensity Therapeutics, Inc. (INTS)

Wed, 19 Aug 2026 06:46:10 -0400

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $7.00 price target on Intensity Therapeutics, Inc. (NASDAQ: INTS).

The analyst commented: "On August 11, Intensity reported 2Q26 financial results and provided a business update. In April 2026, the company initiated activities to resume enrollment at a limited number of U.S. sites in the INVINCIBLE-3 Study, an open-label, randomized Phase 3 trial of its lead intratumoral candidate, INT230-6, as monotherapy versus standard of care in second- and third-line treatment of certain soft tissue sarcoma subtypes. Enrollment will proceed under an amended protocol that the FDA has reviewed, and management now expects

NeOnc Approaches a Major Biotech Inflection Point as tomorrow’s Brain-Cancer Data is set to Collide with a Tight Float

Tue, 11 Aug 2026 11:00:39 -0400

DENVER, Aug. 11, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies (NASDAQ:NTHI) is heading into Wednesday with the kind of setup that can put a clinical-stage biotech squarely on the market’s radar: a stock trading near its 52-week low, a relatively small trading float, more than 500,000 shares reported short, three Wall Street Buy ratings and a long-awaited brain-cancer data readout.

The question is whether the clinical data can justify the attention.

NeOnc is scheduled to release topline Phase 2a results from its NEO100-01 trial at 8:30 a.m. ET on Wednesday, August 12, evaluating intranasal NEO100 in patients

NeOnc Approaches a Major Biotech Inflection Point as tomorrow’s Brain-Cancer Data is set to Collide with a Tight Float

Tue, 11 Aug 2026 11:00:39 -0400

The question is whether the clinical data can justify the attention.

NeOnc is scheduled to release topline Phase 2a results from its NEO100-01 trial at 8:30 a.m. ET on Wednesday, August 12, evaluating intranasal NEO100 in patients

NeOnc Approaches a Major Biotech Inflection Point as tomorrow’s Brain-Cancer Data is set to Collide with a Tight Float

Tue, 11 Aug 2026 11:00:39 -0400

The question is whether the clinical data can justify the attention.

NeOnc is scheduled to release topline Phase 2a results from its NEO100-01 trial at 8:30 a.m. ET on Wednesday, August 12, evaluating intranasal NEO100 in patients

NeOnc Approaches a Major Biotech Inflection Point as tomorrow’s Brain-Cancer Data is set to Collide with a Tight Float

Tue, 11 Aug 2026 11:00:39 -0400

The question is whether the clinical data can justify the attention.

NeOnc is scheduled to release topline Phase 2a results from its NEO100-01 trial at 8:30 a.m. ET on Wednesday, August 12, evaluating intranasal NEO100 in patients

NeOnc Approaches a Major Biotech Inflection Point as tomorrow’s Brain-Cancer Data is set to Collide with a Tight Float

Tue, 11 Aug 2026 11:00:39 -0400

The question is whether the clinical data can justify the attention.

NeOnc is scheduled to release topline Phase 2a results from its NEO100-01 trial at 8:30 a.m. ET on Wednesday, August 12, evaluating intranasal NEO100 in patients

NeOnc Approaches a Major Biotech Inflection Point as tomorrow’s Brain-Cancer Data is set to Collide with a Tight Float

Tue, 11 Aug 2026 11:00:39 -0400

The question is whether the clinical data can justify the attention.

NeOnc is scheduled to release topline Phase 2a results from its NEO100-01 trial at 8:30 a.m. ET on Wednesday, August 12, evaluating intranasal NEO100 in patients

NeOnc Approaches a Major Biotech Inflection Point as tomorrow’s Brain-Cancer Data is set to Collide with a Tight Float

Tue, 11 Aug 2026 11:00:39 -0400

The question is whether the clinical data can justify the attention.

NeOnc is scheduled to release topline Phase 2a results from its NEO100-01 trial at 8:30 a.m. ET on Wednesday, August 12, evaluating intranasal NEO100 in patients

NeOnc Approaches a Major Biotech Inflection Point as tomorrow’s Brain-Cancer Data is set to Collide with a Tight Float

Tue, 11 Aug 2026 11:00:39 -0400

The question is whether the clinical data can justify the attention.

NeOnc is scheduled to release topline Phase 2a results from its NEO100-01 trial at 8:30 a.m. ET on Wednesday, August 12, evaluating intranasal NEO100 in patients

Intensity Therapeutics, Inc. (INTS) Misses Q2 EPS by 24c

Tue, 11 Aug 2026 08:01:39 -0400

Intensity Therapeutics, Inc. (NASDAQ: INTS) reported Q2 EPS of ($1.11), $0.24 worse than the analyst estimate of ($0.87).

For earnings history and earnings-related data on Intensity Therapeutics, Inc. (INTS) click here.

Form 8-K INTENSITY THERAPEUTICS, For: Aug 11

Tue, 11 Aug 2026 07:41:00 -0400

si-local-file:///var/storage/secattach/20260811/26901503.html

Form 8-K INTENSITY THERAPEUTICS, For: Aug 11

Tue, 11 Aug 2026 07:41:00 -0400

si-local-file:///var/storage/secattach/20260811/26901503.html

Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Tue, 11 Aug 2026 07:30:00 -0400

Initiated activities to resume enrollment in a limited number of U.S. sites in the soft tissue sarcoma Phase 3 INVINCIBLE-3 Study by the third quarter of 2026
Patient treatment restarted in the presurgical triple negative breast cancer ("TNBC") Phase 2 INVINCIBLE-4 Study
Cash and cash equivalents of $9.5 million as of June 30, 2026
Increased business development activities

Conference call begins at 8:00 a.m. Eastern time today